Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Share News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.15
Bid: 8.80
Ask: 9.50
Change: 0.05 (0.55%)
Spread: 0.70 (7.955%)
Open: 9.10
High: 9.15
Low: 8.70
Prev. Close: 9.10
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: Metro Bank Down Amid Mortgage Competition

Wed, 24th Oct 2018 10:43

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Wednesday.----------FTSE 100 - WINNERS----------Barclays, up 0.9%. The bank reported a rise in third quarter profit but year-to-date profit remained lower, dragged by litigation costs and conducts charges experienced earlier in the year.For the three months ended September, Barclays pretax profit increased sharply to GBP1.46 billion from GBP1.11 billion in the third quarter of 2017. The improvement was led by Barclays investment bank, which helped the Barclays International division to a 30% rise in profit. The group raised its third quarter dividend to 2.5 pence from 1.0p paid a year before. Barclays reiterated its intention to pay a total dividend of 6.5p for 2018.----------International Consolidated Airlines Group up 1.5%. Deutsche Bank raised is rating on European Airlines sector to Overweight from Underweight. easyJet was up 0.5%.----------FTSE 100 - LOSERS----------Fresnillo, down 2.7%. The gold miner revised its annual production guidance after having mixed results in the third quarter. The company said gold production in the three months to the end of September 30 declined by 3.5% to 225,000 ounces, while silver production increased by 6.3% year-on-year to 15.5 million ounces. However, Fresnillo said third-quarter silver production was not as high as anticipated and reduced its annual guidance for silver output to between 62.0 million and 64.5 million ounces from 64.5 million to 67.5 million ounces estimated earlier. Fresnillo now expects to produce between 920,000 and 940,000 ounces of gold in the full year, up from 900,000 to 930,000 ounces guided previously. Fellow gold miner Randgold Resources was down 1.7%.----------FTSE 250 - WINNERS----------Equiniti, up 0.6%. The payments services provider won two pension administration contracts in the UK nuclear sector. Under the terms of the contracts, Equiniti's pension division, EQPaymaster, will support virtually all employees and former employees engaged in the UK nuclear industry. The contracts are for the UK Atomic Energy Authority and for the Combined Nuclear Pension Plan, covering 60,000 members in total.----------FTSE 250 - LOSERS----------Metro Bank, down 7.9%. The challenger bank said it is experiencing continued competition in residential mortgages resulting in "slowed margin progress". Net interest margin fell by 15 basis points to 1.82%. More positively, Metro Bank reported lending growth of 52% in the first nine months to GBP13.12 billion from GBP8.61 billion, with commercial loans up 43% to GBP4.17 billion and residential mortgages up 59% to GBP8.72 billion. Underlying pretax profit multiplied to GBP39.2 million from GBP13.2 million, while statutory pretax profit jumped to GBP25.1 million from GBP7.8 million. At the end of the period, the bank's assets stood at GBP20.57 billion, up 41% year-on-year, while its loan to deposit ratio grew to 89% from 80%. Its Common Equity Tier 1 Capital ratio remained robust at 15.7% as at September-end. ----------Stobart Group, down 5.4%. The infrastructure & support services company swung to a loss in the first half of its financial year, despite a 21% increase in revenue. For the six months to August 31, Stobart reported a pretax loss of GBP18.8 million compared with a GBP111.6 million profit in the same period a year ago. Interim revenue increased to GBP151.3 million from GBP124.6 million year-on-year. The company's profit was hurt by the lack of income generated by the sale of its 49% interest in the parent of Eddie Stobart, Greenwhitestar Holding Co 1, which resulted in a GBP123.8 million profit figuring in its interim balance sheet a year ago. ----------OTHER MAIN MARKET AND AIM - WINNERS----------Photo-Me International, up 10%. The photo-booth operator maintained its annual guidance following the completion of restructuring of its Japanese unit. Photo-Me said it removed unprofitable machines and installed new ones with a "significantly" lower production cost. As a result, the company expects to have a 35% faster return on its Japanese investment. Photo-Me said its deployment of encrypted photo ID upload technology has "continued to progress well", with 2,700 photo booths in the UK now enabled for UK passport renewals. The company is now targeting the deployment of 4,000 enabled photo booths by the end of December.----------OTHER MAIN MARKET AND AIM - LOSERS----------Yu Group, down 83%. The gas & electricity supplier said it expects a GBP10 million reduction in profit, which will send it to a loss, after discovering areas of concern in a performance review. One of the areas of concern for the group was the recognition of historic accrued income, which totalled GBP4.2 million for 2017 and GBP4.3 million for the six months to June. The level of trade debtors held also caused concern to the group, as if found that the level of non-payment being experienced is "significantly above that which has been previously provided for". Looking ahead, despite being "extremely disappointed" to reveal the profitability drop, Yu said it expects to achieve a profit in 2019. ----------Scancell Holdings, down 15%. The biopharmaceutical company said the US Food & Drug Administration has asked for further information on its SCIB1 product's proposed trial. Scancell applied for an investigational new drug application to the FDA for SCIB1, which will be trialled in combination with pembrolizumab in patients with advanced melanoma. The trial is being carried out alongside Ichor Medical Systems Inc's TriGrid electroporation delivery system, and it is further information on this that the US regulator has asked for. The system, Scancell said, has been used on the previous SCIB1 phase 1/2 stud, which had favourable results.----------
More News
11 Apr 2022 13:10

Scancell opens recruitment for cancer therapy trial

(Sharecast News) - Immunotherapy developer Scancell announced on Monday that its phase 1 and 2 clinical trial with 'Modi-1' is open for recruitment.

Read more
11 Apr 2022 12:02

LONDON MARKET MIDDAY: CAC moves green for Macron, FTSE 100 lags

(Alliance News) - Stocks in Europe were having a mixed day on Monday, with the FTSE 100 feeling the weight of a poor UK GDP reading, but the CAC 40 in Paris gaining as investors in France show confidence in President Emmanuel Macron - as he looks set to extend his time in office.

Read more
11 Apr 2022 11:17

Scancell shares soar as clinical trial opens for recruitment

(Alliance News) - Scancell Holdings PLC shares soared on Monday after the cancer immunotherapies developer said its phase 1/2 clinical trial with Modi-1 has opened for recruitment.

Read more
29 Mar 2022 19:21

IN BRIEF: Scancell broadens Covidity clinical trial in South Africa

Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Updates on South African Health Products Regulatory Authority's approval of a protocol amendment to the phase 1 Covidity clinical trial being conducted at the University of Cape Town Lung Institute in South Africa.

Read more
17 Mar 2022 21:02

TRADING UPDATES: SimiGon merger to go ahead; Segro launches green bond

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
22 Feb 2022 11:50

Image Scan sinks as it expects to post significant loss in first half

(Alliance News) - Image Scan Holdings PLC shares tanked on Tuesday after the company said it expects to post a significant loss for the first half of financial 2022 and thinks it is "unlikely" that the second half will fully recover the loss.

Read more
31 Jan 2022 22:07

TRADING UPDATES: MJ Hudson and Tandem see results ahead of views

TRADING UPDATES: MJ Hudson and Tandem see results ahead of views

Read more
26 Jan 2022 20:18

TRADING UPDATES: Somero upbeat after strong year; Scancell in profit

TRADING UPDATES: Somero upbeat after strong year; Scancell in profit

Read more
19 Jan 2022 16:02

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
19 Nov 2021 13:49

Scancell treats first patient in melanoma tumour trial

(Sharecast News) - Cancer and infectious disease immunotherapy developer Scancell announced on Friday that the enrolment and treatment of the first patient had taken place in its multicentre phase 2 clinical trial of its 'SCIB1' tumour treatment at the Churchill Hospital in Oxford.

Read more
19 Nov 2021 11:37

IN BRIEF: Scancell starts SCIB1 phase 2 trial in UK after pause

IN BRIEF: Scancell starts SCIB1 phase 2 trial in UK after pause

Read more
16 Nov 2021 16:09

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
2 Nov 2021 15:20

DIRECTOR DEALINGS: MD of Gleeson Homes buys GBP150,000 in shares

DIRECTOR DEALINGS: MD of Gleeson Homes buys GBP150,000 in shares

Read more
1 Nov 2021 06:57

IN BRIEF: Kings Arms Yard VCT appoints two new non-executive directors

IN BRIEF: Kings Arms Yard VCT appoints two new non-executive directors

Read more
29 Oct 2021 20:28

TRADING UPDATES: Asia Dragon beats benchmark, Henderson Far East lags

TRADING UPDATES: Asia Dragon beats benchmark, Henderson Far East lags

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.